Spero Therapeutics announced that the Food and Drug Administration (FDA) has granted Fast Track designation for SPR994 (tebipenem pivoxil hydrobromide) for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)
Polymyxin B recommended for routine use in invasive infections; colistin preferred for lower UTI
Findings from a small study suggest it could be an effective, safe, and attractive alternative to fluoroquinolones, bacterial resistance to which is becoming increasingly prevalent.
Plazomicin is superior to meropenem in treating complicated UTIs due Enterobacteriaceae not susceptible to aminoglycosides.
Research team used novel algorithms to ID early symptoms of health declines in dementia patients.
For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.
Poor clinical outcomes linked to extended spectrum cephalosporin-resistant Enterobacteriaceae.
To investigate the risk of cardiovascular adverse effects associated with this antibiotic class, researchers conducted a systematic review, meta-analysis, and network meta-analysis using studies identified through a search of MEDLINE, EMBASE, and the Cochrane Library.
Results from phase 2 study in patients with multidrug-resistant Gram-negative uropathogens.
Depletion of Lactobacillus iners in the bladder appears to increase the risk of urinary tract infection following urogynecologic surgery, study finds.